Andrew J Carroll

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2320034/publications.pdf

Version: 2024-02-01

		94433	32842
162	10,584	37	100
papers	citations	h-index	g-index

163	163	163	11105
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 2002, 100, 4325-4336.	1.4	1,444
2	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1005-1015.	27.0	1,161
3	Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood, 2008, 111, 5477-5485.	1.4	751
4	IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2010, 28, 2348-2355.	1.6	699
5	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nature Genetics, 2017, 49, 1211-1218.	21.4	693
6	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood, 2007, 109, 926-935.	1.4	413
7	Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2008, 26, 5078-5087.	1.6	294
8	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Childrenâ€™s Oncology Group study AALL0232. Blood, 2015, 126, 964-971.	1.4	287
9	Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature, 2014, 508, 98-102.	27.8	261
10	ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood, 2011, 118, 6920-6929.	1.4	246
11	RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures. Journal of Clinical Oncology, 2012, 30, 3109-3118.	1.6	242
12	Targetable kinase gene fusions in high-risk B-ALL: a study from the Childrenâ€™s Oncology Group. Blood, 2017, 129, 3352-3361.	1.4	236
13	Wilmsâ€™ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2008, 26, 4595-4602.	1.6	230
14	Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2005, 23, 9234-9242.	1.6	226
15	BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood, 2003, 102, 1613-1618.	1.4	222
16	Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18679-18684.	7.1	214
17	FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood, 2010, 116, 3622-3626.	1.4	201
18	Prognostic Significance of Expression of a Single MicroRNA, miR-181a, in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2010, 28, 5257-5264.	1.6	176

#	Article	IF	Citations
19	Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients. Journal of Clinical Oncology, 2013, 31, 2086-2093.	1.6	165
20	Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2009, 27, 3198-3204.	1.6	149
21	Childrenâ€™s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2020, 38, 3282-3293.	1.6	136
22	Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score. Journal of Clinical Oncology, 2014, 32, 548-556.	1.6	134
23	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	1.4	110
24	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Childrenâ€™s Oncology Group Trial AALL0331. Journal of Clinical Oncology, 2020, 38, 602-612.	1.6	107
25	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Childrenâ€™s Oncology Group. Blood, 2018, 132, 815-824.	1.4	97
26	Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood, 2004, 103, 4036-4042.	1.4	96
27	Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Advances, 2018, 2, 1645-1650.	5.2	85
28	Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia, 2018, 32, 1338-1348.	7.2	80
29	Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (â€œPh-likeâ€•or â€œBCR-ABL1-Likeâ€) Signature For Therapeutic Targeting and Clinical Intervention. Blood, 2013, 122, 826-826.	1.4	65
30	Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/ KMT2A. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26340-26346.	7.1	59
31	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. Journal of Clinical Oncology, 2021, 39, 1437-1447.	1.6	56
32	Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood, 2007, 110, 1105-1111.	1.4	52
33	Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. International Journal of Oncology, 2008, 33, 239-44.	3.3	50
34	The recurrent distal 22q11.2 microdeletions are often de novo and do not represent a single clinical entity: a proposed categorization system. Genetics in Medicine, 2014, 16, 92-100.	2.4	49
35	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very highâ€risk stratum of patients with newly diagnosed highâ€risk Bâ€lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer, 2018, 124, 1150-1159.	4.1	46
36	FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Childrenâ€™s Oncology Group trial AALL0631. Leukemia, 2021, 35, 1279-1290.	7.2	46

#	Article	IF	Citations
37	HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. Leukemia, 2021, 35, 3040-3043.	7.2	42
38	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Childrenâ€™s Oncology Group Study AALL1131. Journal of Clinical Oncology, 2020, 38, 2628-2638.	1.6	41
39	Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. Cancer Discovery, 2021, 11, 626-637.	9.4	41
40	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood, 2019, 134, 1227-1237.	1.4	37
41	Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features. Cancer Causes and Control, 2016, 27, 81-91.	1.8	35
42	NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia, 2018, 32, 2536-2545.	7.2	33
43	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. Cancer Genetics, 2019, 238, 62-68.	0.4	32
44	Mixedâ€phenotype acute leukemia: A cohort and consensus research strategy from the Childrenâ€™s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. Cancer, 2020, 126, 593-601.	4.1	32
45	Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. Cancer Genetics, 2015, 208, 1-18.	0.4	30
46	Terminal deletion of the long arm of chromosome 4 in a mother and two sons. Clinical Genetics, 1996, 50, 538-540.	2.0	29
47	Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene, 2019, 38, 2241-2262.	5.9	29
48	Clinical and functional significance of circular RNAs in cytogenetically normal AML. Blood Advances, 2020, 4, 239-251.	5.2	29
49	Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica, 2017, 102, 1391-1400.	3.5	28
50	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica, 2019, 104, 986-992.	3.5	25
51	Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. Leukemia, 2014, 28, 1754-1758.	7.2	24
52	Clinical relevance of small copy-number variants in chromosomal microarray clinical testing. Genetics in Medicine, 2017, 19, 377-385.	2.4	24
53	Interstitial deletion of chromosome 1 [del(1)(q25q32)] in an infant with prune belly sequence. Prenatal Diagnosis, 1988, 8, 169-174.	2.3	22
54	Mutations associated with a 17-gene leukemia stem cell score and the scoreâ€™s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. Haematologica, 2020, 105, 721-729.	3.5	21

#	Article	IF	Citations
55	Hyperdiploidy andE2A-PBX1 fusion in an adult with t(1;19)+ acute lymphoblastic leukemia: Case report and review of the literature. , 1997, 20, 392-398.		20
56	Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. Blood Advances, 2021, 5, 1474-1482.	5.2	20
57	Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. Journal of Clinical Oncology, 2021, 39, 1540-1552.	1.6	19
58	An Acute Myeloproliferative Disorder Characterized by Myelofibrosis and Blast Cells that Express Phenotypic Properties Associated with Multiple Hematopoietic Lineages. American Journal of Clinical Pathology, 1985, 83, 114-121.	0.7	17
59	Outcome of Children with Standardâ€Risk Tâ€Lineage Acute Lymphoblastic Leukemiaâ€”Comparison among Different Treatment Strategies. Pediatric Blood and Cancer, 2016, 63, 255-261.	1.5	17
60	Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia. Blood Advances, 2022, 6, 1371-1380.	5.2	16
61	The translocation (1;14)(p34;q11) in human t-cell leukemia: Chromosome breakage 25 kilobase pairs downstream of thetal1 protooncogene. Genes Chromosomes and Cancer, 1992, 4, 211-216.	2.8	15
62	Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. Leukemia, 2019, 33, 771-775.	7.2	15
63	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Advances, 2021, 5, 2775-2787.	5.2	15
64	Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Childrenâ€™s Oncology Group Study AALL0232. Leukemia, 2022, 36, 648-655.	7.2	14
65	Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Childrenâ€™s Oncology Group (COG) AALL0331. Blood, 2013, 122, 837-837.	1.4	13
66	Mutations in Genes Associated with Familial Predisposition to Myeloid Neoplasms: Their Frequency and Associations with Pretreatment Characteristics in Adult Patients (Pts) with Presumably Sporadic De Novo Acute Myeloid Leukemia (AML). Blood, 2018, 132, 1478-1478.	1.4	13
67	Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. Clinical Cancer Research, 2019, 25, 6524-6531.	7.0	12
68	Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434. Blood, 2015, 126, 794-794.	1.4	12
69	Sexâ€based disparities in outcome in pediatric acute lymphoblastic leukemia: a Childrenâ€™s Oncology Group report. Cancer, 2022, 128, 1863-1870.	4.1	12
70	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Childrenâ€™s Oncology Group. Haematologica, 2019, 104, e517-e520.	3.5	11
71	Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Childrenâ€™s Oncology Group AALL0631 trial. Haematologica, 2022, 107, 1205-1208.	3.5	11
72	Prognostic impact of minimal residual disease at the end of consolidation in NCI standardâ€risk Bâ€lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2021, 68, e28929.	1.5	9

#	Article	IF	Citations
73	Establishment and genomic characterization of a sporadic malignant peripheral nerve sheath tumor cell line. Scientific Reports, 2021, 11, 5690.	3.3	9
74	Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (â‰¥60) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study.. Blood, 2009, 114, 326-326.	1.4	9
75	Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Childrenâ€™s Oncology Group Studies P9904 and P9905. Leukemia, 2020, 34, 1006-1016.	7.2	8
76	Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia. Blood, 2013, 122, 232-232.	1.4	8
77	Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. Blood, 2013, 122, 825-825.	1.4	8
78	Overview of Clinical Cytogenetics. Current Protocols in Human Genetics, 2016, 89, 8.1.1-8.1.13.	3.5	7
79	Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. Molecular Cancer Therapeutics, 2019, 18, 1451-1459.	4.1	7
80	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. Blood, 2018, 132, 35-35.	1.4	7
81	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. Blood, 2009, 114, 1580-1580.	1.4	7
82	Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622. Blood, 2012, 120, 137-137.	1.4	7
83	PI3K/AKT/mTOR Signaling Is a Significant Druggable Pathway In Infant Acute Lymphoblastic Leukemia (ALL). Blood, 2013, 122, 1669-1669.	1.4	7
84	Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932. Blood, 2019, 134, 824-824.	1.4	6
85	Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group. Blood, 2020, 136, 45-46.	1.4	6
86	Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG).. Blood, 2009, 114, 2598-2598.	1.4	6
87	Specific MLL Partner Genes in Infant Acute Lymphoblastic Leukemia (ALL) Associated with Outcome Are Linked to Age and White Blood Cell Count (WBC) at Diagnosis: A Report On the Children's Oncology Group (COG) P9407 Trial.. Blood, 2009, 114, 907-907.	1.4	5
88	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). Blood, 2015, 126, 807-807.	1.4	5
89	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. Blood, 2019, 134, 649-649.	1.4	5
90	Pre-B-Cell Acute Lymphoblastic Leukemia in Childhood. Leukemia and Lymphoma, 1990, 3, 1-6.	1.3	4

#	Article	IF	Citations
91	Klinefelter syndrome and 47,<scp>XYY</scp> syndrome in children with B cell acute lymphoblastic leukaemia. British Journal of Haematology, 2017, 179, 843-846.	2.5	4
92	Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. Haematologica, 2022, 107, 1034-1044.	3.5	4
93	FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study. Blood, 2019, 134, 1293-1293.	1.4	4
94	Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance). Blood, 2020, 136, 5-7.	1.4	4
95	Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group. Blood, 2016, 128, 451-451.	1.4	4
96	Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define â€œAcute Myeloid Leukemia (AML) with Myelodysplasia-Related Changesâ€• in Adults: a Cancer and Leukemia Group B (CALGB) Study.. Blood, 2009, 114, 2602-2602.	1.4	3
97	Genome-Wide Analysis of Genetic Alterations In Hypodiploid Acute Lymphoblastic Leukemia Identifies a High Frequency of Mutations Targeting the IKAROS Gene Family and Ras Signaling. Blood, 2010, 116, 411-411.	1.4	3
98	Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232. Blood, 2011, 118, 1440-1440.	1.4	3
99	A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232. Blood, 2011, 118, 743-743.	1.4	3
100	Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance). Blood, 2020, 136, 20-21.	1.4	2
101	Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [â‰¥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.. Blood, 2009, 114, 1579-1579.	1.4	2
102	Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study.. Blood, 2009, 114, 1616-1616.	1.4	2
103	Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study. Blood, 2010, 116, 577-577.	1.4	2
104	Predicting Clinical Dose-Exposure and Exposure-Response Relationships of Pan-Antiapoptotic BCL-2 Family Inhibitor Obatoclax in MLL Rearranged Infant Leukemias From Preclinical Disease Models and Adult Experience. Blood, 2011, 118, 2580-2580.	1.4	2
105	Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts). Blood, 2011, 118, 414-414.	1.4	2
106	Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Blood, 2015, 126, 694-694.	1.4	2
107	Secondary Chromosomal Abnormalities Appear to Be Less Prognostic for Children with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with Intensified Imatinib and Chemotherapy: Results of the Children's Oncology Group (COG) Study AALL0031.. Blood, 2009, 114, 2606-2606.	1.4	2
108	iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies. Blood, 2011, 118, 739-739.	1.4	2

#	Article	IF	Citations
109	High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance). Blood, 2021, 138, 221-221.	1.4	2
110	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. Blood, 2020, 136, 39-40.	1.4	2
111	Relapse after Prolonged Remission in Philadelphia-Like Acute Lymphoblastic Leukemia. Case Reports in Hematology, 2019, 2019, 1-3.	0.4	1
112	Additional Gene Mutations Refine the 2017 European Leukemianet (ELN) Classification of Adult Patients (Pts) with De Novo Acute Myeloid Leukemia (AML) Aged <60 Years: An Analysis of Alliance for Clinical Trials in Oncology (Alliance) Studies. Blood, 2018, 132, 2740-2740.	1.4	1
113	The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment. Blood, 2019, 134, 2681-2681.	1.4	1
114	Cytogenetic Subgroups Drive Risk Stratification and Response to Chemotherapy and Blinatumomab in Children and Young Adults with Relapsed B-ALL: A Children's Oncology Group Study. Blood, 2020, 136, 16-17.	1.4	1
115	Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Childrenâ€™s Oncology Group (COG) Study AALL0031.. Blood, 2008, 112, 911-911.	1.4	1
116	Gene Expression Profiling in Down Syndrome Acute Lymphoblastic Leukemia Identifies Distinct Profiles Associated with CRLF2 Expression Status.. Blood, 2009, 114, 2389-2389.	1.4	1
117	Infant Acute Lymphoblastic Leukemias Are Pan-Sensitive to Obatoclax Across molecular/Cytogenetic Subtypes, Especially MLL-ENL, and gene Expression Profiles Determine Obatoclax IC50: A Report on the Children's Oncology Group (COG) P9407 Trial. Blood, 2010, 116, 2757-2757.	1.4	1
118	The Clinical Role of Micrornas (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts). Blood, 2012, 120, 1387-1387.	1.4	1
119	Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. Blood, 2013, 122, 3736-3736.	1.4	1
120	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). Blood, 2016, 128, 758-758.	1.4	1
121	VpreB Surrogate Light Chain Expression in B-Lineage ALL: A Report from the Children's Oncology Group. Blood Advances, 2021, , .	5.2	1
122	Pan-Anti-Apoptotic BCL-2 Family Inhibitor, Obatoclax, Activates Autophagic Cell Death Pathway and Has Potent Cytotoxicity in Infant and Pediatric MLL-Rearranged Leukemias. Blood, 2008, 112, 2647-2647.	1.4	1
123	Genomic- and Transcriptomic Profiling Of Acute Lymphoblastic Leukemia With Dicentric Chromosomes. Blood, 2013, 122, 234-234.	1.4	1
124	Whole Exome Sequencing of Pediatric Acute Lymphoblastic Leukemia Patients Identify Mutations in 11 Pathways: A Report from the Children's Oncology Group. Blood, 2016, 128, 455-455.	1.4	1
125	Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance). Blood, 2019, 134, 1247-1247.	1.4	1
126	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). Blood, 2020, 136, 44-45.	1.4	1

#	Article	IF	Citations
127	Response to interferon treatment in essential thrombocythemia with inv(3)(q21q26). Annals of Hematology, 2019, 98, 2845-2846.	1.8	0
128	Acute Lymphoblastic Leukemia (ALL) with t(8;14)(q11.2;q32): B-Lineage Disease with High Proportion of Down Syndrome. A Childrenâ€™s Oncology Group (COG) Study.. Blood, 2008, 112, 1477-1477.	1.4	0
129	Gene Expression Profiling Differentiates Childhood Acute Lymphoblastic Leukemia in Down Syndrome Versus Non-Down Syndrome Patients.. Blood, 2008, 112, 1203-1203.	1.4	0
130	Cell Death Regulatory Gene Expression Correlates with MLL Rearrangement Status and Prognostic Clinical Covariates in Acute Leukemia in Infants.. Blood, 2008, 112, 2255-2255.	1.4	0
131	Rearrangement of CRLF2 in B-Progenitor and Down Syndrome Associated Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 182-182.	1.4	0
132	Aberrant Gene Expression of BAALC and ERG in Older [â‰¥60 Years (y)] De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study.. Blood, 2009, 114, 214-214.	1.4	0
133	Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710.. Blood, 2010, 116, 1038-1038.	1.4	0
134	Targeted Microarray Analyses Augment the Clinical Cytogenetic Diagnosis of Acute Lymphoblastic Leukemia (ALL): Submicroscopic Genetic Events Improve Diagnosis, Contribute to Risk Stratification, and Provide Genetic Markers for Minimal Residual Disease (MRD) Testing. Blood, 2010, 116, 2690-2690.	1.4	0
135	Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study. Blood, 2010, 116, 98-98.	1.4	0
136	Gene Expression Profiling Reveals Genes Predictive of Outcome In Infant Acute Lymphoblastic Leukemia (ALL) and Distinctive Age-Related Gene Expression Profiles (< 90 Days vs. > 90 Days): A Children's Oncology Group Study. Blood, 2010, 116, 412-412.	1.4	0
137	Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures,. Blood, 2011, 118, 3454-3454.	1.4	0
138	Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16). Blood, 2011, 118, 2514-2514.	1.4	0
139	MLL Rearrangement and Age At Diagnosis Are Strongly Associated with High Level Surface FLT3 Expression and Ex Vivo Sensitivity to FLT3 Inhibition: A Prospective Analysis of 54 Consecutive Infants with ALL Enrolled in Children's Oncology Group (COG) Trial AALL0631. Blood, 2011, 118, 568-568.	1.4	0
140	ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet â€˜Favorable' Genetic Category. Blood, 2011, 118, 417-417.	1.4	0
141	Intrachromosomal Amplification of Chromosome 21(iAMP21): Cytogenetic Characterisation and Outcome in Childhood B-Cell Precursor Acute Lymphoblastic Leukaemia (BCP-ALL). A Study On Behalf of the Ponte Di Legno International Childhood ALL Workshop. Blood, 2012, 120, 293-293.	1.4	0
142	Expression Profiling for MEIS1 and HOXA9/10 Identifies an Increased Incidence of MLL Rearrangements in T-ALL: A Children's Oncology Group Study.. Blood, 2012, 120, 2505-2505.	1.4	0
143	Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). Blood, 2013, 122, 2540-2540.	1.4	0
144	Cytogenetics and Outcome Of Infants With Acute Lymphoblastic Leukemia and Absence Of MLL Rearrangements. Blood, 2013, 122, 1349-1349.	1.4	0

#	Article	IF	Citations
145	Leukemic Blasts With The PNH Phenotype: Correlation With Cytogenetics In ALL. Blood, 2013, 122, 2628-2628.	1.4	0
146	Integrated Genomic Analysis of Down Syndrome Acute Lymphoblastic Leukemia Reveals Recurrent Cancer Gene Alterations and Evidence of Frequent Subclonal Driver Events. Blood, 2016, 128, 4083-4083.	1.4	0
147	New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia. Blood, 2016, 128, 2906-2906.	1.4	0
148	Improved Diagnosis of Intrachromosomal Amplification of Chromosome 21 (iAMP21) By Copy Number Profiling. Blood, 2016, 128, 1733-1733.	1.4	0
149	The Mutational Patterns Associated with Cytogenetic Subsets of De Novo Acute Myeloid Leukemia (AML): A Study of 1603 Adult Patients (Pts). Blood, 2016, 128, 287-287.	1.4	0
150	CCND1 and CCND2 Mutations Are Frequent in Adults with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) with t(8;21)(q22;q22). Blood, 2016, 128, 2740-2740.	1.4	0
151	Uniparental Disomies (UPD) of Chromosome 13q Is Associated with Shorter Disease-Free Survival in Adult Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). Blood, 2018, 132, 2777-2777.	1.4	0
152	Prognostic and Biologic Significance of Long Non-Coding RNA (lncRNA) Profiling in Cytogenetically Abnormal Acute Myeloid Leukemia (CA-AML). Blood, 2018, 132, 2767-2767.	1.4	0
153	Genome-Wide Association Study (GWAS) Identifies a Significant Acute Myeloid Leukemia (AML) Susceptibility Locus Near BICRA. Blood, 2018, 132, 85-85.	1.4	0
154	Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). Blood, 2019, 134, 2694-2694.	1.4	0
155	Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Algorithm in Patients (Pts) Treated on Cancer and Leukemia Group B (CALGB)/Alliance Protocols. Blood, 2019, 134, 182-182.	1.4	0
156	Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232. Blood, 2019, 134, 286-286.	1.4	0
157	Epigenetic Phenocopying Expands Molecular Risk Assessment in Acute Myeloid Leukemia (Alliance). Blood, 2021, 138, 803-803.	1.4	0
158	Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes. Blood, 2021, 138, 685-685.	1.4	0
159	Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance). Blood, 2021, 138, 226-226.	1.4	0
160	White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance). Blood, 2021, 138, 3369-3369.	1.4	0
161	Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Variants Associated with Risk of 11q23/KMT2A-Translocated and Core-Binding Factor (CBF) AML and Suggests a Role for Transcription Elongation in Leukemogenesis. Blood, 2020, 136, 29-30.	1.4	0
162	Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy. Blood, 2020, 136, 40-41.	1.4	0